<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-14T09:01:22Z</responseDate>
  <request identifier="oai:figshare.com:article/33776357" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33776357</identifier>
        <datestamp>2026-09-15T07:42:34Z</datestamp>
        <setSpec>category_37339</setSpec>
        <setSpec>category_37351</setSpec>
        <setSpec>category_37360</setSpec>
        <setSpec>category_37366</setSpec>
        <setSpec>category_37375</setSpec>
        <setSpec>portal_1012</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Supplementary Tables S1-S10 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer</dc:title>
          <dc:creator>Darren Cowzer (19426132)</dc:creator>
          <dc:creator>Henry Walch (16147974)</dc:creator>
          <dc:creator>Pranita Atri (14948053)</dc:creator>
          <dc:creator>Farheen Shah (21739556)</dc:creator>
          <dc:creator>Risha Huq (24916148)</dc:creator>
          <dc:creator>Rohit Thummalapalli (17314483)</dc:creator>
          <dc:creator>Fatema Nagib (24916151)</dc:creator>
          <dc:creator>Anna Varghese (24916154)</dc:creator>
          <dc:creator>Danny N. Khalil (24223855)</dc:creator>
          <dc:creator>Wungki Park (15047199)</dc:creator>
          <dc:creator>Benoit Rousseau (15119656)</dc:creator>
          <dc:creator>Andrea Cercek (16147992)</dc:creator>
          <dc:creator>Joseph Erinjeri (21468970)</dc:creator>
          <dc:creator>Randy Yeh (24916157)</dc:creator>
          <dc:creator>Richard K. Do (15015501)</dc:creator>
          <dc:creator>Olca Basturk (15050976)</dc:creator>
          <dc:creator>Jinru Shia (15123504)</dc:creator>
          <dc:creator>Debyani Chakravarty (15050961)</dc:creator>
          <dc:creator>Michael F. Berger (15048171)</dc:creator>
          <dc:creator>Nikolaus Schultz (15050967)</dc:creator>
          <dc:creator>Mithat Gonen (14947720)</dc:creator>
          <dc:creator>Eileen M. O’Reilly (10580187)</dc:creator>
          <dc:creator>William Jarnagin (15050970)</dc:creator>
          <dc:creator>Ghassan K. Abou-Alfa (15012734)</dc:creator>
          <dc:creator>David B. Solit (14955541)</dc:creator>
          <dc:creator>Walid K. Chatila (17098946)</dc:creator>
          <dc:creator>James J. Harding (15032705)</dc:creator>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Tumor Biology</dc:subject>
          <dc:subject>Therapeutic Research and Development</dc:subject>
          <dc:subject>Clinical Research and Trials</dc:subject>
          <dc:subject>Methods and Technology</dc:subject>
          <dc:subject>Drug Resistance</dc:subject>
          <dc:subject>Drug Targets</dc:subject>
          <dc:subject>Gastrointestinal Cancers</dc:subject>
          <dc:subject>Gene Technologies</dc:subject>
          <dc:subject>Precision Medicine</dc:subject>
          <dc:subject>Tumor Evolution</dc:subject>
          <dc:description>&lt;p&gt;Table S1. Cohort demographics Table S2: Clinically eligible for matched-targeted therapy cohort demographics of molecularly defined Subgroups Table S3: Genes included on MSK-IMPACT Panels Table S4: Comparison of gene-level alteration frequency by BTC Subtypes Table S5: Comparison of pathway-level alteration frequency by BTC Subtypes Table S6: Actionable alterations in patients without targeted therapy due to unavailability Table S7: Comparison of clinical characteristics between treatment groups Table S8: Comparison of gene-level alterations between treatment groups Table S9: Summary of OS univariate analysis (Full cohort) Table S10: Overall Survival analysis of Molecularly Defined Subgroups&lt;/p&gt;</dc:description>
          <dc:date>2026-09-15T00:00:00Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.1158/1078-0432.33776357</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Supplementary_Tables_S1-S10_from_Molecular_and_Clinical_Determinants_of_Targeted_Therapy_Treatment_in_Biliary_Tract_Cancer/33776357</dc:relation>
          <dc:rights>CC BY</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
